|
Oct 7
|
BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients
|
|
Jul 29
|
BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Small Lung Cancer Trial
|
|
Aug 22
|
BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer
|